Obesity in Hispanic Children with Leukemia

西班牙裔白血病儿童肥胖

• 批准号: 6839625
• 负责人: JACQUES G BAILLARGEON
• 金额: $ 7.3万
• 依托单位: UNIVERSITY OF TEXAS HLTH SCIENCE CENTER
• 依托单位国家: 美国
• 财政年份: 2004
• 资助国家: 美国
• 起止时间: 2004-07-01 至 2006-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6839625
• 关键词: Hispanic Americans; adolescence (12-20); asparaginase; biomarker; body composition; cancer risk; child (0-11); children; clinical research; comorbidity; dosage; gender difference; human subject; leukemia; longitudinal human study; neoplasm /cancer chemotherapy; neoplasm /cancer relapse /recurrence; obesity; patient oriented research; socioeconomics

DESCRIPTION (provided by applicant): Obesity has long been recognized as one of the most frequently occurring late effects after therapy for childhood acute lymphoblastic leukemia (ALL). A number of factors, including exposure to corticosteroids, exposure to cranial irradiation, and diminished exercise capacity reportedly contribute to increased rates of obesity among ALL survivors. The development of obesity during or following ALL treatment places survivors at increased risk for hypertension, type II diabetes, cardiovascular disease, persistent adulthood obesity, and recurrence of cancer. Childhood cancer patients who are already obese at the time of diagnosis represent a particular challenge for the oncologist. Obesity may complicate chemotherapy dose determination. Moreover, treatment-related weight gain may exacerbate the obese patient's already increased risk for many short- and long-term health effects. In view of the growing epidemic of childhood obesity in the general population, understanding the relationship between obesity status at the initiation of ALL therapy and weight gain and associated medical problems both during and following treatment is critically important. Because Hispanic adolescents exhibit exceedingly high rates of obesity, these research questions hold particular relevance to Hispanic Americans. The present study will rely on a historic cohort of 425 pediatric ALL patients treated at one of four institutions that comprise the South Texas Pediatric CCOP between 1990-2000. This patient population, which is 80% Hispanic, provides a unique opportunity to examine the impact of obesity at diagnosis on treatment, survivorship, and subsequent weight gain patterns. Our preliminary findings show that 18% of the patient population was obese and 22% is at risk for obesity at the time of diagnosis. The primary goals of the present study are to: 1) identify risk factors for obesity among ALL patients both during and following completion of chemotherapy; 2) quantify the extent of chemotherapy dose reduction in obese ALL patients; and 3) assess obesity as a prognostic factor in ALL patients.

描述（由申请人提供）： 肥胖长期以来一直被认为是儿童急性淋巴细胞白血病（ALL）治疗后最常发生的晚期效应之一。据报道，许多因素，包括接触皮质类固醇、接触颅脑辐射和运动能力下降，都会导致 ALL 幸存者的肥胖率增加。 ALL 治疗期间或治疗后出现肥胖会增加幸存者患高血压、II 型糖尿病、心血管疾病、成年期持续肥胖和癌症复发的风险。在诊断时已经肥胖的儿童癌症患者对肿瘤科医生来说是一个特殊的挑战。肥胖可能会使化疗剂量的确定变得复杂。此外，与治疗相关的体重增加可能会加剧肥胖患者已经增加的许多短期和长期健康影响的风险。鉴于儿童肥胖症在普通人群中日益流行，了解 ALL 治疗开始时的肥胖状况与治疗期间和治疗后体重增加以及相关医疗问题之间的关系至关重要。由于西班牙裔青少年的肥胖率极高，因此这些研究问题与西班牙裔美国人尤其相关。本研究将依赖于 425 名儿童 ALL 患者的历史队列，这些患者在 1990 年至 2000 年间在南德克萨斯儿科 CCOP 的四个机构之一接受治疗。该患者群体中 80% 是西班牙裔，为检查诊断时肥胖对治疗、生存和随后体重增加模式的影响提供了独特的机会。我们的初步研究结果显示，诊断时 18% 的患者群体患有肥胖症，22% 的患者存在肥胖风险。本研究的主要目标是：1）确定 ALL 患者化疗期间和完成后肥胖的危险因素； 2) 量化肥胖 ALL 患者化疗剂量减少的程度； 3) 评估肥胖作为 ALL 患者的预后因素。